Hi there. I started this account to communicate my thoughts on how to advance breast cancer diagnosis and therapy. #bcsm

See the PAM50 analysis of the ALTERNATE neoadjuvant endocrine therapy trial at SABCS. Despite high ER by IHC for eligibility, 7% were non luminal subtypes and NET was almost completely ineffective. Data should be considered in new neoadjuvant/adjuvant endocrine study designs.

See cancer research (Gao, X et al) on ESR1 fusion genes. Here the LBD of ER is replaced with sequences from many partner genes to generate a highly active ER chimera that can’t be targeted by ET. Look for these in studies of new SERDs upon progression. Thx DOD BCRP and Helis Fdn

Listening again to Lisa Carey’s summary of TNBC at SABCS. Masterful and recommended to all. The reality is we don’t understand the cause of TNBC outside of Inherited BRCA. Sporadic TNBC have poorly understood DNA repair defects beyond homologous recombination that are critical

Here is the link to Gou paper link on ESR1 translocations and their diagnosis and functional significance cancerres.aacrjournals.org/content/canres…. Congrats Xuxu on the publication.

Congrats to Xuxu Gou on making the cover of Cancer Research on her paper on ESR1 fusion genes. We are now working on targeted therapy for these profound endocrine therapy resistance events.

Oncology is hard for everyone: full of triumph and tragedy. For me the wild places full of tranquility and the natural world are a stress anecdote. Attached is a photo of a remote hike in Nevada today at Kraft Mountain in Red Rock mountain conservation area . Recommended!

I am excited to share that I will start with AZ on March 7th as SVP for Early Oncology. I deeply appreciate all the faculty I have worked with @BCM and I am very grateful for the support from our donors, my collaborators and the patients I cared for.

Sorry @BCM should be Baylor College of Medicine. Just learning the twitter thing!